MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies
MELK is a therapeutic target by regulating RFA efficacy in HCC, and targeting MELK via RGD-LNPs provides new insight into improving RFA efficacy in HCC clinical treatment and combating the malignant progression of liver cancer.
Authors
- Zhongwei Zhao (ORCID: https://orcid.org/0000-0002-6175-5664)
- Bufu Tang (ORCID: https://orcid.org/0000-0003-3525-4433)
- Qiaoyou Weng (ORCID: https://orcid.org/0000-0003-0023-4598)
- Minjiang Chen (ORCID: https://orcid.org/0000-0002-4040-6115)
- Xiaojie Zhang (ORCID: https://orcid.org/0000-0002-6211-7576)
- Jingjing Song (ORCID: https://orcid.org/0000-0003-0506-4671)
- Jiansong Ji (ORCID: https://orcid.org/0000-0002-6026-3676)
- Biao Chen (ORCID: https://orcid.org/0000-0003-1852-5289)
- Weiqian Chen (ORCID: https://orcid.org/0000-0003-3819-7841)
- Wangting Xu
- Yang Yang (ORCID: https://orcid.org/0000-0003-4697-1470)
- Yajie Wang (ORCID: https://orcid.org/0000-0002-7479-980X)
- Jiayi Ding (ORCID: https://orcid.org/0009-0003-3617-5160)
- Jinyu Zhu (ORCID: https://orcid.org/0000-0002-7811-752X)
- Shiji Fang
- Lin Shen
- Liyun Zheng (ORCID: https://orcid.org/0000-0001-7750-4109)
- Rongfang Qiu (ORCID: https://orcid.org/0000-0002-4945-2345)
Institutions
- Wenzhou Medical University (CN)
- Sir Run Run Shaw Hospital (CN)
- Lishui University (CN)
- Lishui Central Hospital (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Military Medical Research
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1186/s40779-024-00588-7
- Citations
- 9
- Primary Topic
- Cancer Mechanisms and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 13.24
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province